Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics's CTX-131?
CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Metastatic Renal Cell...